FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to new compounds of formula 
or to pharmaceutically acceptable salts thereof for treating the Flaviviridae infection, as well as to a pharmaceutical composition thereof, and to the use thereof in preparing a drug. In the compound of formula (IVa), the base* represents a purine or pyrimidine base; R1 and R2 together form a cyclic 3',5'-phosphate ester; R7 represents halogen, particularly F or Cl; Y3 independently represents H, F, Cl, Br or I.
EFFECT: preparing the compounds for treating the Flaviviridae infection.
22 cl, 32 ex, 4 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| MODIFIED 2- AND 3-NUCLEOSIDES AND USE THEREOF TO PRODUCE MEDICINAL AGENT, HAVING HEPATITIS C INHIBITING ACTIVITY | 2003 |
|
RU2437892C2 |
| PROMEDICINES OF MODIFIED 2'- AND 3'-NUCLEOSIDES FOR TREATMENT OF FLAVIVIRIDAE INFECTIONS | 2003 |
|
RU2366661C2 |
| COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS | 2007 |
|
RU2525392C2 |
| COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS | 2007 |
|
RU2466729C2 |
| β-D-2ʹ-DEOXY-2ʹ-α-FLUORO-2ʹ-β-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR TREATMENT OF DISEASES CAUSED BY HCV | 2016 |
|
RU2764767C2 |
| COMBINATED INHIBITORS OF FBP-ASE AND ANTIDIABETIC AGENTS FOR DIABETES TREATMENT | 2001 |
|
RU2328308C2 |
| COMBINED THERAPY INCLUDING SGLT INHIBITORS AND DPP4 INHIBITORS | 2009 |
|
RU2481106C2 |
| MONOMER DERIVATIVES OF GLYCOPEPTIDE ANTIBIOTIC | 2005 |
|
RU2424248C2 |
| PROLONGED-RELEASE COMPOSITION, CONTAINING PEPTIDES AS ACTIVE INGREDIENTS | 2012 |
|
RU2633483C2 |
| COMBINATION OF INHIBITORS OF FBP-ASE AND SENSITIZING AGENTS OF INSULIN FOR DIABETES MELLITUS TREATMENT | 1999 |
|
RU2227749C2 |
